We assessed the diagnostic potential of cardiovascular disease-associated microRNAs for the early prediction of gestational diabetes mellitus (GDM) in singleton pregnancies of Caucasian descent in the absence of other pregnancy-related complications. Whole peripheral venous blood samples were collected within 10 to 13 weeks of gestation. This retrospective study involved all pregnancies diagnosed with only GDM (n = 121) and 80 normal term pregnancies selected with regard to equality of sample storage time. Gene expression of 29 microRNAs was assessed using real-time RT-PCR. Upregulation of 11 microRNAs (miR-1-3p, miR-20a-5p, miR-20b-5p, miR-23a-3p, miR-100-5p, miR-125b-5p, miR-126-3p, miR-181a-5p, miR-195-5p, miR-499a-5p, and miR-574-3p) was observed in pregnancies destinated to develop GDM. Combined screening of all 11 dysregulated microRNAs showed the highest accuracy for the early identification of pregnancies destinated to develop GDM. This screening identified 47.93% of GDM pregnancies at a 10.0% false positive rate (FPR). The predictive model for GDM based on aberrant microRNA expression profile was further improved via the implementation of clinical characteristics (maternal age and BMI at early stages of gestation and an infertility treatment by assisted reproductive technology). Following this, 69.17% of GDM pregnancies were identified at a 10.0% FPR. The effective prediction model specifically for severe GDM requiring administration of therapy involved using a combination of these three clinical characteristics and three microRNA biomarkers (miR-20a-5p, miR-20b-5p, and miR-195-5p). This model identified 78.95% of cases at a 10.0% FPR. The effective prediction model for GDM managed by diet only required the involvement of these three clinical characteristics and eight microRNA biomarkers (miR-1-3p, miR-20a-5p, miR-20b-5p, miR-100-5p, miR-125b-5p, miR-195-5p, miR-499a-5p, and miR-574-3p). With this, the model identified 50.50% of GDM pregnancies managed by diet only at a 10.0% FPR. When other clinical variables such as history of miscarriage, the presence of trombophilic gene mutations, positive first-trimester screening for preeclampsia and/or fetal growth restriction by the Fetal Medicine Foundation algorithm, and family history of diabetes mellitus in first-degree relatives were included in the GDM prediction model, the predictive power was further increased at a 10.0% FPR (72.50% GDM in total, 89.47% GDM requiring therapy, and 56.44% GDM managed by diet only). Cardiovascular disease-associated microRNAs represent promising early biomarkers to be implemented into routine first-trimester screening programs with a very good predictive potential for GDM.

Department of Molecular Biology and Cell Pathology 3rd Faculty of Medicine Charles University 100 00 Prague Czech Republic

Institute for the Care of the Mother and Child 3rd Faculty of Medicine Charles University 147 00 Prague Czech Republic

Zobrazit více v PubMed

Committee on Practice Bulletins—Obstetrics ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet. Gynecol. 2018;131:e49–e64. doi: 10.1097/AOG.0000000000002501. PubMed DOI

International Association of Diabetes and Pregnancy Study Groups Consensus Panel. Metzger B.E., Gabbe S.G., Persson B., Buchanan T.A., Catalano P.A., Damm P., Dyer A.R., Leiva A.D., Hod M., et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:676–682. doi: 10.2337/dc10-0719. PubMed DOI PMC

American Diabetes Association Diagnosis and classification of diabetes mellitus (Position Statement) Diabetes Care. 2009;32:S62–S67. doi: 10.2337/dc09-S062. PubMed DOI PMC

England L.J., Dietz P.M., Njoroge T., Callaghan W.M., Bruce C., Buus R.M., Williamson D.F. Preventing type 2 diabetes: Public health implications for women with a history of gestational diabetes mellitus. Am. J. Obstet. Gynecol. 2009;200:365.e1–365.e8. doi: 10.1016/j.ajog.2008.06.031. PubMed DOI

O’Sullivan J.B. Body weight and subsequent diabetes mellitus. JAMA. 1982;248:949–952. doi: 10.1001/jama.1982.03330080031024. PubMed DOI

Kim C., Newton K.M., Knopp R.H. Gestational diabetes and the incidence of type 2 diabetes: A systematic review. Diabetes Care. 2002;25:1862–1868. doi: 10.2337/diacare.25.10.1862. PubMed DOI

International Diabetes Federation IDF GDM Model of Care. [(accessed on 16 May 2022)]. Available online: https://www.idf.org/e-library/guidelines/77-idf-gdm-model-of-care-implementation-protocol-guidelines-for-healthcare-professionals.html.

National Institute for Health and Care Excellence (NICE) Diabetes in Pregnancy: Management from Preconception to the Postnatal Period. [(accessed on 16 May 2022)]. Available online: https://www.guidelines.co.uk/diabetes/nice-diabetes-in-pregnancy-guideline/252595.article. PubMed

Syngelaki A., Pastides A., Kotecha R., Wright A., Akolekar R., Nicolaides K.H. First-Trimester Screening for Gestational Diabetes Mellitus Based on Maternal Characteristics and History. Fetal Diagn. Ther. 2015;38:14–21. doi: 10.1159/000369970. PubMed DOI

Nanda S., Savvidou M., Syngelaki A., Akolekar R., Nicolaides K.H. Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat. Diagn. 2011;31:135–141. doi: 10.1002/pd.2636. PubMed DOI

Sweeting A.N., Appelblom H., Ross G.P., Wong J., Kouru H., Williams P.F., Sairanen M., Hyett J.A. First trimester prediction of gestational diabetes mellitus: A clinical model based on maternal demographic parameters. Diabetes Res. Clin. Pract. 2017;127:44–50. doi: 10.1016/j.diabres.2017.02.036. PubMed DOI

Sweeting A.N., Wong J., Appelblom H., Ross G.P., Kouru H., Williams P.F., Sairanen M., Hyett J.A. A Novel Early Pregnancy Risk Prediction Model for Gestational Diabetes Mellitus. Fetal Diagn. Ther. 2019;45:76–84. doi: 10.1159/000486853. PubMed DOI

Wang P., Ma H.H., Hou X.Z., Song L.L., Song X.L., Zhang J.F. Reduced plasma level of irisin in first trimester as a risk factor for the development of gestational diabetes mellitus. Diabetes Res. Clin. Pract. 2018;142:130–138. doi: 10.1016/j.diabres.2018.05.038. PubMed DOI

Wu Y.T., Zhang C.J., Mol B.W., Kawai A., Li C., Chen L., Wang Y., Sheng J.Z., Fan J.X., Shi Y., et al. Early Prediction of Gestational Diabetes Mellitus in the Chinese Population via Advanced Machine Learning. J. Clin. Endocrinol. Metab. 2021;106:e1191–e1205. doi: 10.1210/clinem/dgaa899. PubMed DOI PMC

Kumar M., Chen L., Tan K., Ang L.T., Ho C., Wong G., Soh S.E., Tan K.H., Chan J.K.Y., Godfrey K.M., et al. Population-centric risk prediction modeling for gestational diabetes mellitus: A machine learning approach. Diabetes Res. Clin. Pract. 2022;185:109237. doi: 10.1016/j.diabres.2022.109237. PubMed DOI PMC

Sakurai K., Eguchi A., Watanabe M., Yamamoto M., Ishikawa K., Mori C. Exploration of predictive metabolic factors for gestational diabetes mellitus in Japanese women using metabolomic analysis. J. Diabetes Investig. 2019;10:513–520. doi: 10.1111/jdi.12887. PubMed DOI PMC

Tenenbaum-Gavish K., Sharabi-Nov A., Binyamin D., Møller H.J., Danon D., Rothman L., Hadar E., Idelson A., Vogel I., Koren O., et al. First trimester biomarkers for prediction of gestational diabetes mellitus. Placenta. 2020;101:80–89. doi: 10.1016/j.placenta.2020.08.020. PubMed DOI

Zheng Y., Hou W., Xiao J., Huang H., Quan W., Chen Y. Application Value of Predictive Model Based on Maternal Coagulation Function and Glycolipid Metabolism Indicators in Early Diagnosis of Gestational Diabetes Mellitus. Front. Public Health. 2022;10:850191. doi: 10.3389/fpubh.2022.850191. PubMed DOI PMC

Xiong Y., Lin L., Chen Y., Salerno S., Li Y., Zeng X., Li H. Prediction of gestational diabetes mellitus in the first 19 weeks of pregnancy using machine learning techniques. J. Matern. Fetal Neonatal Med. 2022;35:2457–2463. doi: 10.1080/14767058.2020.1786517. PubMed DOI

Zhang Y.Z., Zhou L., Tian L., Li X., Zhang G., Qin J.Y., Zhang D.D., Fang H. A mid-pregnancy risk prediction model for gestational diabetes mellitus based on the maternal status in combination with ultrasound and serological findings. Exp. Ther. Med. 2020;20:293–300. doi: 10.3892/etm.2020.8690. PubMed DOI PMC

Cremona A., O’Gorman C.S., Ismail K.I., Hayes K., Donnelly A.E., Hamilton J., Cotter A. A risk-prediction model using parameters of maternal body composition to identify gestational diabetes mellitus in early pregnancy. Clin. Nutr. ESPEN. 2021;45:312–321. doi: 10.1016/j.clnesp.2021.08.002. PubMed DOI

Shaarbaf Eidgahi E., Nasiri M., Kariman N., Safavi Ardebili N., Salehi M., Kazemi M., Zayeri F. Diagnostic accuracy of first and early second trimester multiple biomarkers for prediction of gestational diabetes mellitus: A multivariate longitudinal approach. BMC Pregnancy Childbirth. 2022;22:13. doi: 10.1186/s12884-021-04348-6. PubMed DOI PMC

Lappharat S., Rothmanee P., Jandee K., Suksai M., Liabsuetrakul T. A model for predicting gestational diabetes mellitus in early pregnancy: A prospective study in Thailand. Obstet. Gynecol. Sci. 2022;65:156–165. doi: 10.5468/ogs.21250. PubMed DOI PMC

Wang X., Zheng X., Yan J., Xu R., Xu M., Zheng L., Xu L., Lin Z. The Clinical Values of Afamin, Triglyceride and PLR in Predicting Risk of Gestational Diabetes During Early Pregnancy. Front. Endocrinol. 2021;12:723650. doi: 10.3389/fendo.2021.723650. PubMed DOI PMC

Wang J., Lv B., Chen X., Pan Y., Chen K., Zhang Y., Li Q., Wei L., Liu Y. An early model to predict the risk of gestational diabetes mellitus in the absence of blood examination indexes: Application in primary health care centres. BMC Pregnancy Childbirth. 2021;21:814. doi: 10.1186/s12884-021-04295-2. PubMed DOI PMC

Kang M., Zhang H., Zhang J., Huang K., Zhao J., Hu J., Lu C., Shao J., Weng J., Yang Y., et al. A Novel Nomogram for Predicting Gestational Diabetes Mellitus During Early Pregnancy. Front. Endocrinol. 2021;12:779210. doi: 10.3389/fendo.2021.779210. PubMed DOI PMC

Buerger O., Elger T., Varthaliti A., Syngelaki A., Wright A., Nicolaides K.H. First-Trimester Screening for Gestational Diabetes Mellitus in Twin Pregnancies. J. Clin. Med. 2021;10:3814. doi: 10.3390/jcm10173814. PubMed DOI PMC

Snyder B.M., Baer R.J., Oltman S.P., Robinson J.G., Breheny P.J., Saftlas A.F., Bao W., Greiner A.L., Carter K.D., Rand L., et al. Early pregnancy prediction of gestational diabetes mellitus risk using prenatal screening biomarkers in nulliparous women. Diabetes Res. Clin. Pract. 2020;163:108139. doi: 10.1016/j.diabres.2020.108139. PubMed DOI PMC

Zhang X., Zhao X., Huo L., Yuan N., Sun J., Du J., Nan M., Ji L. Risk prediction model of gestational diabetes mellitus based on nomogram in a Chinese population cohort study. Sci. Rep. 2020;10:21223. doi: 10.1038/s41598-020-78164-x. PubMed DOI PMC

van Hoorn F., Koster M., Naaktgeboren C.A., Groenendaal F., Kwee A., Lamain-de Ruiter M., Franx A., Bekker M.N. Prognostic models versus single risk factor approach in first-trimester selective screening for gestational diabetes mellitus: A prospective population-based multicentre cohort study. BJOG. 2021;128:645–654. doi: 10.1111/1471-0528.16446. PubMed DOI PMC

Benhalima K., Van Crombrugge P., Moyson C., Verhaeghe J., Vandeginste S., Verlaenen H., Vercammen C., Maes T., Dufraimont E., De Block C., et al. Estimating the risk of gestational diabetes mellitus based on the 2013 WHO criteria: A prediction model based on clinical and biochemical variables in early pregnancy. Acta Diabetol. 2020;57:661–671. doi: 10.1007/s00592-019-01469-5. PubMed DOI

Meertens L., Smits L., van Kuijk S., Aardenburg R., van Dooren I., Langenveld J., Zwaan I.M., Spaanderman M., Scheepers H. External validation and clinical usefulness of first-trimester prediction models for small- and large-for-gestational-age infants: A prospective cohort study. BJOG. 2019;126:472–484. doi: 10.1111/1471-0528.15516. PubMed DOI PMC

Pan Y., Hu J., Zhong S. The joint prediction model of pBMI and eFBG in predicting gestational diabetes mellitus. J. Int. Med. Res. 2020;48:300060519889199. doi: 10.1177/0300060519889199. PubMed DOI PMC

Zheng T., Ye W., Wang X., Li X., Zhang J., Little J., Zhou L., Zhang L. A simple model to predict risk of gestational diabetes mellitus from 8 to 20 weeks of gestation in Chinese women. BMC Pregnancy Childbirth. 2019;19:252. doi: 10.1186/s12884-019-2374-8. PubMed DOI PMC

Lamain-de Ruiter M., Kwee A., Naaktgeboren C.A., de Groot I., Evers I.M., Groenendaal F., Hering Y.R., Huisjes A.J., Kirpestein C., Monincx W.M., et al. External validation of prognostic models to predict risk of gestational diabetes mellitus in one Dutch cohort: Prospective multicentre cohort study. BMJ. 2016;354:i4338. doi: 10.1136/bmj.i4338. PubMed DOI

Ravnsborg T., Andersen L.L., Trabjerg N.D., Rasmussen L.M., Jensen D.M., Overgaard M. First-trimester multimarker prediction of gestational diabetes mellitus using targeted mass spectrometry. Diabetologia. 2016;59:970–979. doi: 10.1007/s00125-016-3869-8. PubMed DOI

Hassiakos D., Eleftheriades M., Papastefanou I., Lambrinoudaki I., Kappou D., Lavranos D., Akalestos A., Aravantinos L., Pervanidou P., Chrousos G. Increased Maternal Serum Interleukin-6 Concentrations at 11 to 14 Weeks of Gestation in Low Risk Pregnancies Complicated with Gestational Diabetes Mellitus: Development of a Prediction Model. Horm. Metab. Res. 2016;48:35–41. doi: 10.1055/s-0034-1395659. PubMed DOI

Alptekin H., Çizmecioğlu A., Işık H., Cengiz T., Yildiz M., Iyisoy M.S. Predicting gestational diabetes mellitus during the first trimester using anthropometric measurements and HOMA-IR. J. Endocrinol. Investig. 2016;39:577–583. doi: 10.1007/s40618-015-0427-z. PubMed DOI

Papastefanou I., Eleftheriades M., Kappou D., Lambrinoudaki I., Lavranos D., Pervanidou P., Sotiriadis A., Hassiakos D., Chrousos G.P. Maternal serum osteocalcin at 11–14 weeks of gestation in gestational diabetes mellitus. Eur. J. Clin. Investig. 2015;45:1025–1031. doi: 10.1111/eci.12500. PubMed DOI

Eleftheriades M., Papastefanou I., Lambrinoudaki I., Kappou D., Lavranos D., Akalestos A., Souka A.P., Pervanidou P., Hassiakos D., Chrousos G.P. Elevated placental growth factor concentrations at 11–14 weeks of gestation to predict gestational diabetes mellitus. Metabolism. 2014;63:1419–1425. doi: 10.1016/j.metabol.2014.07.016. PubMed DOI

Li J., Dong X., Wang Z., Wu J. MicroRNA-1 in Cardiac Diseases and Cancers. Korean J. Physiol. Pharmacol. 2014;18:359–363. doi: 10.4196/kjpp.2014.18.5.359. PubMed DOI PMC

Li Y.Q., Zhang M.F., Wen H.Y., Hu C.L., Liu R., Wei H.Y., Ai C.M., Wang G., Liao X.X., Li X. Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. Clinics. 2013;68:75–80. doi: 10.6061/clinics/2013(01)OA12. PubMed DOI PMC

Gasiulė S., Stankevičius V., Patamsytė V., Ražanskas R., Zukovas G., Kapustina Z., Zaliaduonytė D., Benetis R., Lesauskaitė V., Vilkaitis G. Tissue-Specific miRNAs Regulate the Development of Thoracic Aortic Aneurysm: The Emerging Role of KLF4 Network. J. Clin. Med. 2019;8:1609. doi: 10.3390/jcm8101609. PubMed DOI PMC

Gerlinger-Romero F., Yonamine C.Y., Junior D.C., Esteves J.V., Machado U.F. Dysregulation between TRIM63/FBXO32 expression and soleus muscle wasting in diabetic rats: Potential role of miR-1-3p, -29a/b-3p, and -133a/b-3p. Mol. Cell. Biochem. 2017;427:187–199. doi: 10.1007/s11010-016-2910-z. PubMed DOI

Kokkinopoulou I., Maratou E., Mitrou P., Boutati E., Sideris D.C., Fragoulis E.G., Christodoulou M.I. Decreased expression of microRNAs targeting type-2 diabetes susceptibility genes in peripheral blood of patients and predisposed individuals. Endocrine. 2019;66:226–239. doi: 10.1007/s12020-019-02062-0. PubMed DOI

Hromadnikova I., Kotlabova K., Dvorakova L., Krofta L. Evaluation of Vascular Endothelial Function in Young and Middle-Aged Women with Respect to a History of Pregnancy, Pregnancy-Related Complications, Classical Cardiovascular Risk Factors, and Epigenetics. Int. J. Mol. Sci. 2020;21:430. doi: 10.3390/ijms21020430. PubMed DOI PMC

Wang X., Shang Y., Dai S., Wu W., Yi F., Cheng L. MicroRNA-16-5p aggravates myocardial infarction injury by targeting expression of insulin receptor substrates 1 and mediating myocardial apoptosis and angiogenesis. Curr. Neurovasc. Res. 2019 doi: 10.2174/1567202617666191223142743. Epub ahead of print . PubMed DOI

O’Sullivan J.F., Neylon A., McGorrian C., Blake G.J. miRNA-93-5p and other miRNAs as predictors of coronary artery disease and STEMI. Int. J. Cardiol. 2016;224:310–316. doi: 10.1016/j.ijcard.2016.09.016. PubMed DOI

Vegter E.L., Schmitter D., Hagemeijer Y., Ovchinnikova E.S., van der Harst P., Teerlink J.R., O’Connor C.M., Metra M., Davison B.A., Bloomfield D., et al. Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. Int. J. Cardiol. 2016;224:231–239. doi: 10.1016/j.ijcard.2016.09.010. PubMed DOI

Gacoń J., Badacz R., Stępień E., Karch I., Enguita F.J., Żmudka K., Przewłocki T., Kabłak-Ziembicka A. Diagnostic and prognostic micro-RNAs in ischaemic stroke due to carotid artery stenosis and in acute coronary syndrome: A four-year prospective study. Kardiol. Pol. 2018;76:362–369. doi: 10.5603/KP.a2017.0243. PubMed DOI

Zhu Y., Tian F., Li H., Zhou Y., Lu J., Ge Q. Profiling maternal plasma microRNA expression in early pregnancy to predict gestational diabetes mellitus. Int. J. Gynaecol. Obstet. 2015;130:49–53. doi: 10.1016/j.ijgo.2015.01.010. PubMed DOI

Cao Y.L., Jia Y.J., Xing B.H., Shi D.D., Dong X.J. Plasma microRNA-16-5p, -17-5p and -20a-5p: Novel diagnostic biomarkers for gestational diabetes mellitus. J. Obstet. Gynaecol. Res. 2017;43:974–981. doi: 10.1111/jog.13317. PubMed DOI

Hocaoglu M., Demirer S., Senturk H., Turgut A., Komurcu-Bayrak E. Differential expression of candidate circulating microRNAs in maternal blood leukocytes of the patients with preeclampsia and gestational diabetes mellitus. Pregnancy Hypertens. 2019;17:5–11. doi: 10.1016/j.preghy.2019.04.004. PubMed DOI

Duan Y.R., Chen B.P., Chen F., Yang S.X., Zhu C.Y., Ma Y.L., Li Y., Shi J. Exosomal microRNA-16-5p from human urine-derived stem cells ameliorates diabetic nephropathy through protection of podocyte. J. Cell Mol. Med. 2019. Epub ahead of print . PubMed DOI PMC

Assmann T.S., Recamonde-Mendoza M., Costa A.R., Puñales M., Tschiedel B., Canani L.H., Bauer A.C., Crispim D. Circulating miRNAs in diabetic kidney disease: Case-control study and in silico analyses. Acta Diabetol. 2019;56:55–65. doi: 10.1007/s00592-018-1216-x. PubMed DOI

Alicka M., Major P., Wysocki M., Marycz K. Adipose-Derived Mesenchymal Stem Cells Isolated from Patients with Type 2 Diabetes Show Reduced “Stemness” through an Altered Secretome Profile, Impaired Anti-Oxidative Protection, and Mitochondrial Dynamics Deterioration. J. Clin. Med. 2019;8:765. doi: 10.3390/jcm8060765. PubMed DOI PMC

Mogilyansky E., Rigoutsos I. The miR-17/92 cluster: A comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013;20:1603–1614. doi: 10.1038/cdd.2013.125. PubMed DOI PMC

Zhou L., Qi R.Q., Liu M., Xu Y.P., Li G., Weiland M., Kaplan D.H., Mi Q.S. microRNA miR-17-92 cluster is highly expressed in epidermal Langerhans cells but not required for its development. Genes Immun. 2014;15:57–61. doi: 10.1038/gene.2013.61. PubMed DOI

Danielson L.S., Park D.S., Rotllan N., Chamorro-Jorganes A., Guijarro M.V., Fernandez-Hernando C., Fishman G.I., Phoon C.K., Hernando E. Cardiovascular dysregulation of miR-17-92 causes a lethal hypertrophic cardiomyopathy and arrhythmogenesis. FASEB J. 2013;27:1460–1467. doi: 10.1096/fj.12-221994. PubMed DOI PMC

Du W., Pan Z., Chen X., Wang L., Zhang Y., Li S., Liang H., Xu C., Zhang Y., Wu Y., et al. By targeting Stat3 microRNA-17-5p promotes cardiomyocyte apoptosis in response to ischemia followed by reperfusion. Cell. Physiol. Biochem. 2014;34:955–965. doi: 10.1159/000366312. PubMed DOI

Kaucsár T., Révész C., Godó M., Krenács T., Albert M., Szalay C.I., Rosivall L., Benyó Z., Bátkai S., Thum T., et al. Activation of the miR-17 family and miR-21 during murine kidney ischemia-reperfusion injury. Nucleic Acid Ther. 2013;23:344–354. doi: 10.1089/nat.2013.0438. PubMed DOI PMC

Fang L., Ellims A.H., Moore X.L., White D.A., Taylor A.J., Chin-Dusting J., Dart A.M. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. J. Transl. Med. 2015;13:314. doi: 10.1186/s12967-015-0672-0. PubMed DOI PMC

Wu J., Du K., Lu X. Elevated expressions of serum miR-15a, miR-16, and miR-17-5p are associated with acute ischemic stroke. Int. J. Clin. Exp. Med. 2015;8:21071–21079. PubMed PMC

Chen J., Xu L., Hu Q., Yang S., Zhang B., Jiang H. MiR-17-5p as circulating biomarkers for the severity of coronary atherosclerosis in coronary artery disease. Int. J. Cardiol. 2015;197:123–124. doi: 10.1016/j.ijcard.2015.06.037. PubMed DOI

Tian L., Song Z., Shao W., Du W.W., Zhao L.R., Zeng K., Yang B.B., Jin T. Curcumin represses mouse 3T3-L1 cell adipogenic differentiation via inhibiting miR-17-5p and stimulating the Wnt signalling pathway effector Tcf7l. Cell Death Dis. 2017;8:e2559. doi: 10.1038/cddis.2016.455. PubMed DOI PMC

Chen T.C., Sung M.L., Kuo H.C., Chien S.J., Yen C.K., Chen C.N. Differential regulation of human aortic smooth muscle cell proliferation by monocyte-derived macrophages from diabetic patients. PLoS ONE. 2014;9:e113752. PubMed PMC

Mendell J.T. miRiad roles for the miR-17-92 cluster in development and disease. Cell. 2008;133:217–222. doi: 10.1016/j.cell.2008.04.001. PubMed DOI PMC

Brock M., Samillan V.J., Trenkmann M., Schwarzwald C., Ulrich S., Gay R.E., Gassmann M., Ostergaard L., Gay S., Speich R., et al. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. Eur. Heart J. 2014;35:3203–3211. doi: 10.1093/eurheartj/ehs060. PubMed DOI

Pheiffer C., Dias S., Rheeder P., Adam S. Decreased Expression of Circulating miR-20a-5p in South African Women with Gestational Diabetes Mellitus. Mol. Diagn. Ther. 2018;22:345–352. doi: 10.1007/s40291-018-0325-0. PubMed DOI

Platania C.B.M., Maisto R., Trotta M.C., D’Amico M., Rossi S., Gesualdo C., D’Amico G., Balta C., Herman H., Hermenean A., et al. Retinal and circulating miRNA expression patterns in diabetic retinopathy: An in silico and in vivo approach. Br. J. Pharmacol. 2019;176:2179–2194. PubMed PMC

Lareyre F., Clément M., Moratal C., Loyer X., Jean-Baptiste E., Hassen-Khodja R., Chinetti G., Mallat Z., Raffort J. Differential micro-RNA expression in diabetic patients with abdominal aortic aneurysm. Biochimie. 2019;162:1–7. doi: 10.1016/j.biochi.2019.03.012. PubMed DOI

Dickinson B.A., Semus H.M., Montgomery R.L., Stack C., Latimer P.A., Lewton S.M., Lynch J.M., Hullinger T.G., Seto A.G., van Rooij E. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur. J. Heart Fail. 2013;15:650–659. doi: 10.1093/eurjhf/hft018. PubMed DOI

Flowers E., Aouizerat B.E., Abbasi F., Lamendola C., Grove K.M., Fukuoka Y., Reaven G.M. Circulating microRNA-320a and microRNA-486 predict thiazolidinedione response: Moving towards precision health for diabetes prevention. Metabolism. 2015;64:1051–1059. doi: 10.1016/j.metabol.2015.05.013. PubMed DOI PMC

Katayama M., Wiklander O.P.B., Fritz T., Caidahl K., El-Andaloussi S., Zierath J.R., Krook A. Circulating Exosomal miR-20b-5p Is Elevated in Type 2 Diabetes and Could Impair Insulin Action in Human Skeletal Muscle. Diabetes. 2019;68:515–526. doi: 10.2337/db18-0470. PubMed DOI

Xiong Y., Chen L., Yan C., Zhou W., Endo Y., Liu J., Hu L., Hu Y., Mi B., Liu G. Circulating Exosomal miR-20b-5p Inhibition Restores Wnt9b Signaling and Reverses Diabetes-Associated Impaired Wound Healing. Small. 2020;16:e1904044. doi: 10.1002/smll.201904044. PubMed DOI

Zhu K., Hu X., Chen H., Li F., Yin N., Liu A.L., Shan K., Qin Y.W., Huang X., Chang Q., et al. Downregulation of circRNA DMNT3B contributes to diabetic retinal vascular dysfunction through targeting miR-20b-5p and BAMBI. EBioMedicine. 2019;49:341–353. doi: 10.1016/j.ebiom.2019.10.004. PubMed DOI PMC

Sekar D., Venugopal B., Sekar P., Ramalingam K. Role of microRNA 21 in diabetes and associated/related diseases. Gene. 2016;582:14–18. doi: 10.1016/j.gene.2016.01.039. PubMed DOI

Suárez Y., Fernández-Hernando C., Pober J.S., Sessa W.C. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ. Res. 2007;100:1164–1173. doi: 10.1161/01.RES.0000265065.26744.17. PubMed DOI

Dong S., Ma W., Hao B., Hu F., Yan L., Yan X., Wang Y., Chen Z., Wang Z. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int. J. Clin. Exp. Pathol. 2014;7:565–574. PubMed PMC

Zhang J., Xing Q., Zhou X., Li J., Li Y., Zhang L., Zhou Q., Tang B. Circulating miRNA 21 is a promising biomarker for heart failure. Mol. Med. Rep. 2017;16:7766–7774. doi: 10.3892/mmr.2017.7575. PubMed DOI

Licholai S., Blaż M., Kapelak B., Sanak M. Unbiased Profile of MicroRNA Expression in Ascending Aortic Aneurysm Tissue Appoints Molecular Pathways Contributing to the Pathology. Ann. Thorac. Surg. 2016;102:1245–1252. doi: 10.1016/j.athoracsur.2016.03.061. PubMed DOI

Kriegel A.J., Baker M.A., Liu Y., Liu P., Cowley A.W., Jr., Liang M. Endogenous microRNAs in human microvascular endothelial cells regulate mRNAs encoded by hypertension-related genes. Hypertension. 2015;66:793–799. doi: 10.1161/HYPERTENSIONAHA.115.05645. PubMed DOI PMC

Velle-Forbord T., Eidlaug M., Debik J., Sæther J.C., Follestad T., Nauman J., Gigante B., Røsjø H., Omland T., Langaas M., et al. Circulating microRNAs as predictive biomarkers of myocardial infarction: Evidence from the HUNT study. Atherosclerosis. 2019;289:1–7. doi: 10.1016/j.atherosclerosis.2019.07.024. PubMed DOI

Demirsoy İ.H., Ertural D.Y., Balci Ş., Çınkır Ü., Sezer K., Tamer L., Aras N. Profiles of Circulating MiRNAs Following Metformin Treatment in Patients with Type 2 Diabetes. J. Med. Biochem. 2018;37:499–506. doi: 10.2478/jomb-2018-0009. PubMed DOI PMC

Olivieri F., Spazzafumo L., Bonafè M., Recchioni R., Prattichizzo F., Marcheselli F., Micolucci L., Mensà E., Giuliani A., Santini G., et al. MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: Relationship with type 2 diabetes complications. Oncotarget. 2015;6:35372–35382. doi: 10.18632/oncotarget.6164. PubMed DOI PMC

Assmann T.S., Recamonde-Mendoza M., De Souza B.M., Crispim D. MicroRNA expression profiles and type 1 diabetes mellitus: Systematic review and bioinformatic analysis. Endocr. Connect. 2017;6:773–790. doi: 10.1530/EC-17-0248. PubMed DOI PMC

Lakhter A.J., Pratt R.E., Moore R.E., Doucette K.K., Maier B.F., DiMeglio L.A., Sims E.K. Beta cell extracellular vesicle miR-21-5p cargo is increased in response to inflammatory cytokines and serves as a biomarker of type 1 diabetes. Diabetologia. 2018;61:1124–1134. doi: 10.1007/s00125-018-4559-5. PubMed DOI PMC

Grieco G.E., Cataldo D., Ceccarelli E., Nigi L., Catalano G., Brusco N., Mancarella F., Ventriglia G., Fondelli C., Guarino E., et al. Serum Levels of miR-148a and miR-21-5p Are Increased in Type 1 Diabetic Patients and Correlated with Markers of Bone Strength and Metabolism. Noncoding RNA. 2018;4:37. doi: 10.3390/ncrna4040037. PubMed DOI PMC

Gholaminejad A., Abdul Tehrani H., Gholami Fesharaki M. Identification of candidate microRNA biomarkers in diabetic nephropathy: A meta-analysis of profiling studies. J. Nephrol. 2018;31:813–831. doi: 10.1007/s40620-018-0511-5. PubMed DOI

Long B., Gan T.Y., Zhang R.C., Zhang Y.H. miR-23a Regulates Cardiomyocyte Apoptosis by Targeting Manganese Superoxide Dismutase. Mol. Cells. 2017;40:542–549. doi: 10.14348/molcells.2017.0012. PubMed DOI PMC

Wang S., He W., Wang C. MiR-23a Regulates the Vasculogenesis of Coronary Artery Disease by Targeting Epidermal Growth Factor Receptor. Cardiovasc. Ther. 2016;34:199–208. doi: 10.1111/1755-5922.12187. PubMed DOI

Cong X., Li Y., Lu N., Dai Y., Zhang H., Zhao X., Liu Y. Resveratrol attenuates the inflammatory reaction induced by ischemia/reperfusion in the rat heart. Mol. Med. Rep. 2014;9:2528–2532. doi: 10.3892/mmr.2014.2090. PubMed DOI

Černá V., Ostašov P., Pitule P., Moláček J., Třeška V., Pešta M. The Expression Profile of MicroRNAs in Small and Large Abdominal Aortic Aneurysms. Cardiol. Res. Pract. 2019;2019:8645840. doi: 10.1155/2019/8645840. PubMed DOI PMC

Lozano-Bartolomé J., Llauradó G., Portero-Otin M., Altuna-Coy A., Rojo-Martínez G., Vendrell J., Jorba R., Rodríguez-Gallego E., Chacón M.R. Altered Expression of miR-181a-5p and miR-23a-3p Is Associated With Obesity and TNFα-Induced Insulin Resistance. J. Clin. Endocrinol. Metab. 2018;103:1447–1458. doi: 10.1210/jc.2017-01909. PubMed DOI

Dolz S., Górriz D., Tembl J.I., Sánchez D., Fortea G., Parkhutik V., Lago A. Circulating MicroRNAs as Novel Biomarkers of Stenosis Progression in Asymptomatic Carotid Stenosis. Stroke. 2017;48:10–16. doi: 10.1161/STROKEAHA.116.013650. PubMed DOI

De Gonzalo-Calvo D., Cenarro A., Garlaschelli K., Pellegatta F., Vilades D., Nasarre L., Camino-Lopez S., Crespo J., Carreras F., Leta R., et al. Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. J. Mol. Cell. Cardiol. 2017;106:55–67. doi: 10.1016/j.yjmcc.2017.03.005. PubMed DOI

Gecys D., Tatarunas V., Veikutiene A., Lesauskaite V. New potential modulators of CYP4F2 enzyme activity in angina pectoris: Hsa-miR-24-3p and hsa-miR-34a-5p. Biomarkers. 2020;25:40–47. doi: 10.1080/1354750X.2019.1690580. PubMed DOI

Onrat S.T., Onrat E., Ercan Onay E., Yalım Z., Avşar A. The Genetic Determination of the Differentiation between Ischemic Dilated Cardiomyopathy and Idiopathic Dilated Cardiomyopathy. Genet. Test. Mol. Biomark. 2018;22:644–651. doi: 10.1089/gtmb.2018.0188. PubMed DOI

Tan H., Qi J., Fan B.Y., Zhang J., Su F.F., Wang H.T. MicroRNA-24-3p Attenuates Myocardial Ischemia/Reperfusion Injury by Suppressing RIPK1 Expression in Mice. Cell. Physiol. Biochem. 2018;51:46–62. doi: 10.1159/000495161. PubMed DOI

Xiao X., Lu Z., Lin V., May A., Shaw D.H., Wang Z., Che B., Tran K., Du H., Shaw P.X. MicroRNA miR-24-3p Reduces Apoptosis and Regulates Keap1-Nrf2 Pathway in Mouse Cardiomyocytes Responding to Ischemia/Reperfusion Injury. Oxidative Med. Cell. Longev. 2018;2018:7042105. doi: 10.1155/2018/7042105. PubMed DOI PMC

Gao J., Liu Q.G. The role of miR-26 in tumors and normal tissues. Oncol. Lett. 2011;2:1019–1023. doi: 10.3892/ol.2011.413. PubMed DOI PMC

Zheng L., Lin S., Lv C. MiR-26a-5p regulates cardiac fibroblasts collagen expression by targeting ULK1. Sci Rep. 2018;8:2104. doi: 10.1038/s41598-018-20561-4. PubMed DOI PMC

Bye A., Røsjø H., Nauman J., Silva G.J., Follestad T., Omland T., Wisløff U. Circulating microRNAs predict future fatal myocardial infarction in healthy individuals—The HUNT study. J. Mol. Cell. Cardiol. 2016;97:162–168. doi: 10.1016/j.yjmcc.2016.05.009. PubMed DOI

Hsu A., Chen S.J., Chang Y.S., Chen H.C., Chu P.H. Systemic approach to identify serum microRNAs as potential biomarkers for acute myocardial infarction. BioMed Res. Int. 2014;2014:418628. doi: 10.1155/2014/418628. PubMed DOI PMC

Xing X., Guo S., Zhang G., Liu Y., Bi S., Wang X., Lu Q. miR-26a-5p protects against myocardial ischemia/reperfusion injury by regulating the PTEN/PI3K/AKT signaling pathway. Braz. J. Med. Biol. Res. 2020;53:e9106. doi: 10.1590/1414-431x20199106. PubMed DOI PMC

Chouvarine P., Geldner J., Giagnorio R., Legchenko E., Bertram H., Hansmann G. Trans-Right-Ventricle and Transpulmonary MicroRNA Gradients in Human Pulmonary Arterial Hypertension. Pediatr. Crit. Care Med. 2019 doi: 10.1097/PCC.0000000000002207. Epub ahead of print . PubMed DOI

Garavelli S., Bruzzaniti S., Tagliabue E., Prattichizzo F., Di Silvestre D., Perna F., La Sala L., Ceriello A., Mozzillo E., Fattorusso V., et al. Blood Co-Circulating Extracellular microRNAs and Immune Cell Subsets Associate with Type 1 Diabetes Severity. Int. J. Mol. Sci. 2020;21:477. doi: 10.3390/ijms21020477. PubMed DOI PMC

Ye Y., Hu Z., Lin Y., Zhang C., Perez-Polo J.R. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc. Res. 2010;87:535–544. doi: 10.1093/cvr/cvq053. PubMed DOI

Moraes L.N., Fernandez G.J., Vechetti-Júnior I.J., Freire P.P., Souza R.W.A., Villacis R.A.R., Rogatto S.R., Reis P.P., Dal-Pai-Silva M., Carvalho R.F. Integration of miRNA and mRNA expression profiles reveals microRNA-regulated networks during muscle wasting in cardiac cachexia. Sci. Rep. 2017;7:6998. doi: 10.1038/s41598-017-07236-2. PubMed DOI PMC

Zhao Y., Yuan Y., Qiu C. Underexpression of CACNA1C Caused by Overexpression of microRNA-29a Underlies the Pathogenesis of Atrial Fibrillation. Med. Sci. Monit. 2016;22:2175–2181. doi: 10.12659/MSM.896191. PubMed DOI PMC

Zhang L., Zhang Y., Xue S., Ding H., Wang Y., Qi H., Wang Y., Zhu W., Li P. Clinical significance of circulating microRNAs as diagnostic biomarkers for coronary artery disease. J. Cell. Mol. Med. 2020;24:1146–1150. doi: 10.1111/jcmm.14802. PubMed DOI PMC

Wander P.L., Boyko E.J., Hevner K., Parikh V.J., Tadesse M.G., Sorensen T.K., Williams M.A., Enquobahrie D.A. Circulating early- and mid-pregnancy microRNAs and risk of gestational diabetes. Diabetes Res. Clin. Pract. 2017;132:1–9. doi: 10.1016/j.diabres.2017.07.024. PubMed DOI PMC

Kong L., Zhu J., Han W., Jiang X., Xu M., Zhao Y., Dong Q., Pang Z., Guan Q., Gao L., et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: A clinical study. Acta Diabetol. 2011;48:61–69. doi: 10.1007/s00592-010-0226-0. PubMed DOI

Widlansky M.E., Jensen D.M., Wang J., Liu Y., Geurts A.M., Kriegel A.J., Liu P., Ying R., Zhang G., Casati M., et al. miR-29 contributes to normal endothelial function and can restore it in cardiometabolic disorders. EMBO Mol. Med. 2018;10:e8046. doi: 10.15252/emmm.201708046. PubMed DOI PMC

Bulent Vatan M., Kalaycı Yigin A., Akdemir R., Tarik Agac M., Akif Cakar M., Aksoy M., Tatli E., Kilic H., Gunduz H., Guzel D., et al. Altered Plasma MicroRNA Expression in Patients with Mitral Chordae Tendineae Rupture. J. Heart Valve Dis. 2016;25:580–588. PubMed

Gumus G., Giray D., Bobusoglu O., Tamer L., Karpuz D., Hallioglu O. MicroRNA values in children with rheumatic carditis: A preliminary study. Rheumatol. Int. 2018;38:1199–1205. doi: 10.1007/s00296-018-4069-2. PubMed DOI

Rogg E.M., Abplanalp W.T., Bischof C., John D., Schulz M.H., Krishnan J., Fischer A., Poluzzi C., Schaefer L., Bonauer A., et al. Analysis of Cell Type-Specific Effects of MicroRNA-92a Provides Novel Insights Into Target Regulation and Mechanism of Action. Circulation. 2018;138:2545–2558. doi: 10.1161/CIRCULATIONAHA.118.034598. PubMed DOI

Marques F.Z., Vizi D., Khammy O., Mariani J.A., Kaye D.M. The transcardiac gradient of cardio-microRNAs in the failing heart. Eur. J. Heart Fail. 2016;18:1000–1008. doi: 10.1002/ejhf.517. PubMed DOI

Liu Y., Li Q., Hosen M.R., Zietzer A., Flender A., Levermann P., Schmitz T., Frühwald D., Goody P., Nickenig G., et al. Atherosclerotic Conditions Promote the Packaging of Functional MicroRNA-92a-3p Into Endothelial Microvesicles. Circ. Res. 2019;124:575–587. doi: 10.1161/CIRCRESAHA.118.314010. PubMed DOI

Wiese C.B., Zhong J., Xu Z.Q., Zhang Y., Ramirez Solano M.A., Zhu W., Linton M.F., Sheng Q., Kon V., Vickers K.C. Dual inhibition of endothelial miR-92a-3p and miR-489-3p reduces renal injury-associated atherosclerosis. Atherosclerosis. 2019;282:121–131. doi: 10.1016/j.atherosclerosis.2019.01.023. PubMed DOI PMC

Moncini S., Salvi A., Zuccotti P., Viero G., Quattrone A., Barlati S., De Petro G., Venturin M., Riva P. The role of miR-103 and miR-107 in regulation of CDK5R1 expression and in cellular migration. PLoS ONE. 2011;6:e20038. doi: 10.1371/journal.pone.0020038. PubMed DOI PMC

Huang L., Li L., Chen X., Zhang H., Shi Z. MiR-103a targeting Piezo1 is involved in acute myocardial infarction through regulating endothelium function. Cardiol. J. 2016;23:556–562. doi: 10.5603/CJ.a2016.0056. PubMed DOI

Deng B., Du J., Hu R., Wang A.P., Wu W.H., Hu C.P., Li Y.J., Li X.H. MicroRNA-103/107 is involved in hypoxia-induced proliferation of pulmonary arterial smooth muscle cells by targeting HIF-1β. Life Sci. 2016;147:117–124. doi: 10.1016/j.lfs.2016.01.043. PubMed DOI

Trajkovski M., Hausser J., Soutschek J., Bhat B., Akin A., Zavolan M., Heim M.H., Stoffel M. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474:649–653. doi: 10.1038/nature10112. PubMed DOI

Assmann T.S., Recamonde-Mendoza M., Puñales M., Tschiedel B., Canani L.H., Crispim D. MicroRNA expression profile in plasma from type 1 diabetic patients: Case-control study and bioinformatic analysis. Diabetes Res. Clin. Pract. 2018;141:35–46. doi: 10.1016/j.diabres.2018.03.044. PubMed DOI

Shaham L., Binder V., Gefen N., Borkhardt A., Izraeli S. MiR-125 in normal and malignant hematopoiesis. Leukemia. 2012;26:2011–2018. doi: 10.1038/leu.2012.90. PubMed DOI

Tiedt S., Prestel M., Malik R., Schieferdecker N., Duering M., Kautzky V., Stoycheva I., Böck J., Northoff B.H., Klein M., et al. RNA-Seq Identifies Circulating miR-125a-5p, miR-125b-5p, and miR-143-3p as Potential Biomarkers for Acute Ischemic Stroke. Circ. Res. 2017;121:970–980. doi: 10.1161/CIRCRESAHA.117.311572. PubMed DOI

Jia K., Shi P., Han X., Chen T., Tang H., Wang J. Diagnostic value of miR-30d-5p and miR-125b-5p in acute myocardial infarction. Mol. Med. Rep. 2016;14:184–194. doi: 10.3892/mmr.2016.5246. PubMed DOI PMC

Bayoumi A.S., Park K.M., Wang Y., Teoh J.P., Aonuma T., Tang Y., Su H., Weintraub N.L., Kim I.M. A carvedilol-responsive microRNA, miR-125b-5p protects the heart from acute myocardial infarction by repressing pro-apoptotic bak1 and klf13 in cardiomyocytes. J. Mol. Cell. Cardiol. 2018;114:72–82. doi: 10.1016/j.yjmcc.2017.11.003. PubMed DOI PMC

Lamadrid-Romero M., Solís K.H., Cruz-Reséndiz M.S., Pérez J.E., Díaz N.F., Flores-Herrera H., García-López G., Perichart O., Reyes-Muñoz E., Arenas-Huertero F., et al. Central nervous system development-related microRNAs levels increase in the serum of gestational diabetic women during the first trimester of pregnancy. Neurosci. Res. 2018;130:8–22. doi: 10.1016/j.neures.2017.08.003. PubMed DOI

Satake E., Pezzolesi M.G., Md Dom Z.I., Smiles A.M., Niewczas M.A., Krolewski A.S. Circulating miRNA Profiles Associated With Hyperglycemia in Patients With Type 1 Diabetes. Diabetes. 2018;67:1013–1023. doi: 10.2337/db17-1207. PubMed DOI PMC

Samandari N., Mirza A.H., Kaur S., Hougaard P., Nielsen L.B., Fredheim S., Mortensen H.B., Pociot F. Influence of Disease Duration on Circulating Levels of miRNAs in Children and Adolescents with New Onset Type 1 Diabetes. Noncoding RNA. 2018;4:35. doi: 10.3390/ncrna4040035. PubMed DOI PMC

Yu C.Y., Yang C.Y., Rui Z.L. MicroRNA-125b-5p improves pancreatic β-cell function through inhibiting JNK signaling pathway by targeting DACT1 in mice with type 2 diabetes mellitus. Life Sci. 2019;224:67–75. doi: 10.1016/j.lfs.2019.01.031. PubMed DOI

Wu X.J., Zhao Z.F., Kang X.J., Wang H.J., Zhao J., Pu X.M. MicroRNA-126-3p suppresses cell proliferation by targeting PIK3R2 in Kaposi’s sarcoma cells. Oncotarget. 2016;7:36614–36621. doi: 10.18632/oncotarget.9311. PubMed DOI PMC

Matsha T.E., Kengne A.P., Hector S., Mbu D.L., Yako Y.Y., Erasmus R.T. MicroRNA profiling and their pathways in South African individuals with prediabetes and newly diagnosed type 2 diabetes mellitus. Oncotarget. 2018;9:30485–30498. doi: 10.18632/oncotarget.25271. PubMed DOI PMC

Lan X., Wu L., Wu N., Chen Q., Li Y., Du X., Wei C., Feng L., Li Y., Osoro E.K., et al. Long Noncoding RNA lnc-HC Regulates PPARγ-Mediated Hepatic Lipid Metabolism through miR-130b-3p. Mol. Ther. Nucleic Acids. 2019;18:954–965. doi: 10.1016/j.omtn.2019.10.018. PubMed DOI PMC

Tryggestad J.B., Vishwanath A., Jiang S., Mallappa A., Teague A.M., Takahashi Y., Thompson D.M., Chernausek S.D. Influence of gestational diabetes mellitus on human umbilical vein endothelial cell miRNA. Clin. Sci. 2016;130:1955–1967. doi: 10.1042/CS20160305. PubMed DOI PMC

Zhang J., Jazii F.R., Haghighi M.M., Alvares D., Liu L., Khosraviani N., Adeli K. miR-130b is a potent stimulator of hepatic very-low-density lipoprotein assembly and secretion via marked induction of microsomal triglyceride transfer protein. Am. J. Physiol. Endocrinol. Metab. 2020;318:E262–E275. doi: 10.1152/ajpendo.00276.2019. PubMed DOI

Li P., Zhang Q., Wu X., Yang X., Zhang Y., Li Y., Jiang F. Circulating microRNAs serve as novel biological markers for intracranial aneurysms. J. Am. Heart Assoc. 2014;3:e000972. doi: 10.1161/JAHA.114.000972. PubMed DOI PMC

Tian C., Li Z., Yang Z., Huang Q., Liu J., Hong B. Plasma MicroRNA-16 Is a Biomarker for Diagnosis, Stratification, and Prognosis of Hyperacute Cerebral Infarction. PLoS ONE. 2016;11:e0166688. doi: 10.1371/journal.pone.0166688. PubMed DOI PMC

Prabu P., Rome S., Sathishkumar C., Aravind S., Mahalingam B., Shanthirani C.S., Gastebois C., Villard A., Mohan V., Balasubramanyam M. Circulating MiRNAs of ‘Asian Indian Phenotype’ Identified in Subjects with Impaired Glucose Tolerance and Patients with Type 2 Diabetes. PLoS ONE. 2015;10:e0128372. doi: 10.1371/journal.pone.0128372. PubMed DOI PMC

Feng T., Li K., Zheng P., Wang Y., Lv Y., Shen L., Chen Y., Xue Z., Li B., Jin L., et al. Weighted Gene Coexpression Network Analysis Identified MicroRNA Coexpression Modules and Related Pathways in Type 2 Diabetes Mellitus. Oxidative Med. Cell. Longev. 2019;2019:9567641. doi: 10.1155/2019/9567641. PubMed DOI PMC

Liang H.W., Yang X., Wen D.Y., Gao L., Zhang X.Y., Ye Z.H., Luo J., Li Z.Y., He Y., Pang Y.Y., et al. Utility of miR 133a 3p as a diagnostic indicator for hepatocellular carcinoma: An investigation combined with GEO, TCGA, meta analysis and bioinformatics. Mol. Med. Rep. 2018;17:1469–1484. doi: 10.3892/mmr.2017.8040. PubMed DOI PMC

van Rooij E., Olson E.N. MicroRNAs: Powerful new regulators of heart disease and provocative therapeutic targets. J. Clin. Investig. 2007;117:2369–2376. doi: 10.1172/JCI33099. PubMed DOI PMC

Wang J., Xu R., Lin F., Zhang S., Zhang G., Hu S., Zheng Z. MicroRNA: Novel regulators involved in the remodeling and reverse remodeling of the heart. Cardiology. 2009;113:81–88. doi: 10.1159/000172616. PubMed DOI

Kukreja R.C., Yin C., Salloum F.N. MicroRNAs: New players in cardiac injury and protection. Mol. Pharmacol. 2011;80:558–564. doi: 10.1124/mol.111.073528. PubMed DOI PMC

Duisters R.F., Tijsen A.J., Schroen B., Leenders J.J., Lentink V., van der Made I., Herias V., van Leeuwen R.E., Schellings M.W., Barenbrug P., et al. miR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 2009;104:170–178. doi: 10.1161/CIRCRESAHA.108.182535. PubMed DOI

Liu W., Ling S., Sun W., Liu T., Li Y., Zhong G., Zhao D., Zhang P., Song J., Jin X., et al. Circulating microRNAs correlated with the level of coronary artery calcification in symptomatic patients. Sci. Rep. 2015;5:16099. doi: 10.1038/srep16099. PubMed DOI PMC

Jiang Y., Zhang M., He H., Chen J., Zeng H., Li J., Duan R. MicroRNA/mRNA profiling and regulatory network of intracranial aneurysm. BMC Med. Genom. 2013;6:36. doi: 10.1186/1755-8794-6-36. PubMed DOI PMC

Liu H., Xiong W., Liu F., Lin F., He J., Liu C., Lin Y., Dong S. Significant role and mechanism of microRNA-143-3p/KLLN axis in the development of coronary heart disease. Am. J. Transl. Res. 2019;11:3610–3619. PubMed PMC

Li C., Li J., Xue K., Zhang J., Wang C., Zhang Q., Chen X., Gao C., Yu X., Sun L. MicroRNA-143-3p promotes human cardiac fibrosis via targeting sprouty3 after myocardial infarction. J. Mol. Cell. Cardiol. 2019;129:281–292. doi: 10.1016/j.yjmcc.2019.03.005. PubMed DOI

Yu B., Zhao Y., Zhang H., Xie D., Nie W., Shi K. Inhibition of microRNA-143-3p attenuates myocardial hypertrophy by inhibiting inflammatory response. Cell Biol. Int. 2018;42:1584–1593. doi: 10.1002/cbin.11053. PubMed DOI

Jiao M., You H.Z., Yang X.Y., Yuan H., Li Y.L., Liu W.X., Jin M., Du J. Circulating microRNA signature for the diagnosis of childhood dilated cardiomyopathy. Sci. Rep. 2018;8:724. doi: 10.1038/s41598-017-19138-4. PubMed DOI PMC

Deng L., Blanco F.J., Stevens H., Lu R., Caudrillier A., McBride M., McClure J.D., Grant J., Thomas M., Frid M., et al. MicroRNA-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial Hypertension. Circ. Res. 2015;117:870–883. doi: 10.1161/CIRCRESAHA.115.306806. PubMed DOI PMC

Shi L., Tian C., Sun L., Cao F., Meng Z. The lncRNA TUG1/miR-145-5p/FGF10 regulates proliferation and migration in VSMCs of hypertension. Biochem. Biophys. Res. Commun. 2018;501:688–695. doi: 10.1016/j.bbrc.2018.05.049. PubMed DOI

Yang X., Niu X., Xiao Y., Lin K., Chen X. MiRNA expression profiles in healthy OSAHS and OSAHS with arterial hypertension: Potential diagnostic and early warning markers. Respir. Res. 2018;19:194. doi: 10.1186/s12931-018-0894-9. PubMed DOI PMC

Toro R., Blasco-Turrión S., Morales-Ponce F.J., Gonzalez P., Martínez-Camblor P., López-Granados A., Brugada R., Campuzano O., Pérez-Serra A., Rosa Longobardo F., et al. Plasma microRNAs as biomarkers for Lamin A/C-related dilated cardiomyopathy. J. Mol. Med. 2018;96:845–856. doi: 10.1007/s00109-018-1666-1. PubMed DOI

Yuan M., Zhang L., You F., Zhou J., Ma Y., Yang F., Tao L. MiR-145-5p regulates hypoxia-induced inflammatory response and apoptosis in cardiomyocytes by targeting CD40. Mol. Cell. Biochem. 2017;431:123–131. doi: 10.1007/s11010-017-2982-4. PubMed DOI

Wu G., Tan J., Li J., Sun X., Du L., Tao S. miRNA-145-5p induces apoptosis after ischemia-reperfusion by targeting dual specificity phosphatase J. Cell. Physiol. 2019;234:16281–16289. doi: 10.1002/jcp.28291. PubMed DOI

Xie X., Peng L., Zhu J., Zhou Y., Li L., Chen Y., Yu S., Zhao Y. miR-145-5p/Nurr1/TNF-α Signaling-Induced Microglia Activation Regulates Neuron Injury of Acute Cerebral Ischemic/Reperfusion in Rats. Front. Mol. Neurosci. 2017;10:383. doi: 10.3389/fnmol.2017.00383. PubMed DOI PMC

Nunez Lopez Y.O., Retnakaran R., Zinman B., Pratley R.E., Seyhan A.A. Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes. Mol. Metab. 2019;20:63–78. doi: 10.1016/j.molmet.2018.11.003. PubMed DOI PMC

Zhang J., Cui C., Xu H. Downregulation of miR-145-5p elevates retinal ganglion cell survival to delay diabetic retinopathy progress by targeting FGF5. Biosci. Biotechnol. Biochem. 2019;83:1655–1662. doi: 10.1080/09168451.2019.1630251. PubMed DOI

Zamanian Azodi M., Rezaei-Tavirani M., Rezaei-Tavirani M., Robati R.M. Gestational Diabetes Mellitus Regulatory Network Identifies hsa-miR-145-5p and hsa-miR-875-5p as Potential Biomarkers. Int. J. Endocrinol. Metab. 2019;17:e86640. doi: 10.5812/ijem.86640. PubMed DOI PMC

Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA. 2006;103:12481–12486. doi: 10.1073/pnas.0605298103. PubMed DOI PMC

Paterson M.R., Kriegel A.J. MiR-146a/b: A family with shared seeds and different roots. Physiol. Genom. 2017;49:243–252. doi: 10.1152/physiolgenomics.00133.2016. PubMed DOI PMC

Zhang X., Ye Z.H., Liang H.W., Ren F.H., Li P., Dang Y.W., Chen G. Down-regulation of miR-146a-5p and its potential targets in hepatocellular carcinoma validated by a TCGA- and GEO-based study. FEBS Open Bio. 2017;7:504–521. doi: 10.1002/2211-5463.12198. PubMed DOI PMC

Wang X., Ha T., Liu L., Zou J., Zhang X., Kalbfleisch J., Gao X., Williams D., Li C. Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury. Cardiovasc. Res. 2013;97:432–442. doi: 10.1093/cvr/cvs356. PubMed DOI PMC

Quan X., Ji Y., Zhang C., Guo X., Zhang Y., Jia S., Ma W., Fan Y., Wang C. Circulating MiR-146a May be a Potential Biomarker of Coronary Heart Disease in Patients with Subclinical Hypothyroidism. Cell. Physiol. Biochem. 2018;45:226–236. doi: 10.1159/000486769. PubMed DOI

Li S.H., Chen L., Pang X.M., Su S.Y., Zhou X., Chen C.Y., Huang L.G., Li J.P., Liu J.L. Decreased miR-146a expression in acute ischemic stroke directly targets the Fbxl10 mRNA and is involved in modulating apoptosis. Neurochem. Int. 2017;107:156–167. doi: 10.1016/j.neuint.2017.01.011. PubMed DOI

Barberio M.D., Kasselman L.J., Playford M.P., Epstein S.B., Renna H.A., Goldberg M., DeLeon J., Voloshyna I., Barlev A., Salama M., et al. Cholesterol efflux alterations in adolescent obesity: Role of adipose-derived extracellular vesical microRNAs. J. Transl. Med. 2019;17:232. doi: 10.1186/s12967-019-1980-6. PubMed DOI PMC

Gaudet A.D., Fonken L.K., Gushchina L.V., Aubrecht T.G., Maurya S.K., Periasamy M., Nelson R.J., Popovich P.G. miR-155 Deletion in Female Mice Prevents Diet-Induced Obesity. Sci. Rep. 2016;6:22862. doi: 10.1038/srep22862. PubMed DOI PMC

Chen L., Zheng S.Y., Yang C.Q., Ma B.M., Jiang D. MiR-155-5p inhibits the proliferation and migration of VSMCs and HUVECs in atherosclerosis by targeting AKT1. Eur. Rev. Med. Pharmacol. Sci. 2019;23:2223–2233. PubMed

Zhu M., Wei Y., Geißler C., Abschlag K., Corbalán Campos J., Hristov M., Möllmann J., Lehrke M., Karshovska E., Schober A. Hyperlipidemia-Induced MicroRNA-155-5p Improves β-Cell Function by Targeting Mafb. Diabetes. 2017;66:3072–3084. doi: 10.2337/db17-0313. PubMed DOI

Li S., Lee C., Song J., Lu C., Liu J., Cui Y., Liang H., Cao C., Zhang F., Chen H. Circulating microRNAs as potential biomarkers for coronary plaque rupture. Oncotarget. 2017;8:48145–48156. doi: 10.18632/oncotarget.18308. PubMed DOI PMC

Mukai N., Nakayama Y., Murakami S., Tanahashi T., Sessler D.I., Ishii S., Ogawa S., Tokuhira N., Mizobe T., Sawa T., et al. Potential contribution of erythrocyte microRNA to secondary erythrocytosis and thrombocytopenia in congenital heart disease. Pediatr. Res. 2018;83:866–873. doi: 10.1038/pr.2017.327. PubMed DOI

Klimczak D., Kuch M., Pilecki T., Żochowska D., Wirkowska A., Pączek L. Plasma microRNA-155-5p is increased among patients with chronic kidney disease and nocturnal hypertension. J. Am. Soc. Hypertens. 2017;11:831–841.e4. doi: 10.1016/j.jash.2017.10.008. PubMed DOI

Wang M., Sun L., Ding W., Cai S., Zhao Q. Ablation alleviates atrial fibrillation by regulating the signaling pathways of endothelial nitric oxide synthase/nitric oxide via miR-155-5p and miR-24-3p. J. Cell. Biochem. 2019;120:4451–4462. doi: 10.1002/jcb.27733. PubMed DOI

Sun X., Sit A., Feinberg M.W. Role of miR-181 family in regulating vascular inflammation and immunity. Trends Cardiovasc. Med. 2014;24:105–112. doi: 10.1016/j.tcm.2013.09.002. PubMed DOI PMC

Hulsmans M., Sinnaeve P., Van der Schueren B., Mathieu C., Janssens S., Holvoet P. Decreased miR-181a expression in monocytes of obese patients is associated with the occurrence of metabolic syndrome and coronary artery disease. J. Clin. Endocrinol. Metab. 2012;97:E1213–E1218. doi: 10.1210/jc.2012-1008. PubMed DOI

Du X., Yang Y., Xu C., Peng Z., Zhang M., Lei L., Gao W., Dong Y., Shi Z., Sun X., et al. Upregulation of miR-181a impairs hepatic glucose and lipid homeostasis. Oncotarget. 2017;8:91362–91378. doi: 10.18632/oncotarget.20523. PubMed DOI PMC

Wu J., Fan C.L., Ma L.J., Liu T., Wang C., Song J.X., Lv Q.S., Pan H., Zhang C.N., Wang J.J. Distinctive expression signatures of serum microRNAs in ischaemic stroke and transient ischaemic attack patients. Thromb. Haemost. 2017;117:992–1001. PubMed

Zhu J., Yao K., Wang Q., Guo J., Shi H., Ma L., Liu H., Gao W., Zou Y., Ge J. Circulating miR-181a as a Potential Novel Biomarker for Diagnosis of Acute Myocardial Infarction. Cell. Physiol. Biochem. 2016;40:1591–1602. doi: 10.1159/000453209. PubMed DOI

Nabih E.S., Andrawes N.G. The Association Between Circulating Levels of miRNA-181a and Pancreatic Beta Cells Dysfunction via SMAD7 in Type 1 Diabetic Children and Adolescents. J. Clin. Lab. Anal. 2016;30:727–731. doi: 10.1002/jcla.21928. PubMed DOI PMC

He J.F., Luo Y.M., Wan X.H., Jiang D. Biogenesis of MiRNA-195 and its role in biogenesis, the cell cycle, and apoptosis. J. Biochem. Mol. Toxicol. 2011;25:404–408. doi: 10.1002/jbt.20396. PubMed DOI

van Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D., Richardson J.A., Olson E.N. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. USA. 2006;103:18255–18260. doi: 10.1073/pnas.0608791103. PubMed DOI PMC

You X.Y., Huang J.H., Liu B., Liu S.J., Zhong Y., Liu S.M. HMGA1 is a new target of miR-195 involving isoprenaline-induced cardiomyocyte hypertrophy. Biochemistry. 2014;79:538–544. doi: 10.1134/S0006297914060078. PubMed DOI

Zampetaki A., Attia R., Mayr U., Gomes R.S., Phinikaridou A., Yin X., Langley S.R., Willeit P., Lu R., Fanshawe B., et al. Role of miR-195 in aortic aneurysmal disease. Circ. Res. 2014;115:857–866. doi: 10.1161/CIRCRESAHA.115.304361. PubMed DOI

Du J., Zheng R., Xiao F., Zhang S., He K., Zhang J., Shao Y. Downregulated MicroRNA-195 in the Bicuspid Aortic Valve Promotes Calcification of Valve Interstitial Cells via Targeting SMAD7. Cell. Physiol. Biochem. 2017;44:884–896. doi: 10.1159/000485356. PubMed DOI

Collares C.V., Evangelista A.F., Xavier D.J., Rassi D.M., Arns T., Foss-Freitas M.C., Foss M.C., Puthier D., Sakamoto-Hojo E.T., Passos G.A., et al. Identifying common and specific microRNAs expressed in peripheral blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients. BMC Res. Notes. 2013;6:491. doi: 10.1186/1756-0500-6-491. PubMed DOI PMC

Tagoma A., Alnek K., Kirss A., Uibo R., Haller-Kikkatalo K. MicroRNA profiling of second trimester maternal plasma shows upregulation of miR-195-5p in patients with gestational diabetes. Gene. 2018;672:137–142. doi: 10.1016/j.gene.2018.06.004. PubMed DOI

Massaro J.D., Polli C.D., Costa e Silva M., Alves C.C., Passos G.A., Sakamoto-Hojo E.T., de Holanda Miranda W.R., Bispo Cezar N.J., Rassi D.M., Crispim F., et al. Post-transcriptional markers associated with clinical complications in Type 1 and Type 2 diabetes mellitus. Mol. Cell. Endocrinol. 2019;490:1–14. doi: 10.1016/j.mce.2019.03.008. PubMed DOI

Li M., Luan L., Liu Q., Liu Y., Lan X., Li Z., Liu W. MiRNA-199a-5p Protects Against Cerebral Ischemic Injury by Down-Regulating DDR1 in Rats. World Neurosurg. 2019;131:e486–e494. doi: 10.1016/j.wneu.2019.07.203. PubMed DOI

Yan M., Yang S., Meng F., Zhao Z., Tian Z., Yang P. MicroRNA 199a-5p induces apoptosis by targeting JunB. Sci. Rep. 2018;8:6699. doi: 10.1038/s41598-018-24932-9. PubMed DOI PMC

Lynch S.M., Ward M., McNulty H., Angel C.Z., Horigan G., Strain J.J., Purvis J., Tackett M., McKenna D.J. Serum levels of miR-199a-5p correlates with blood pressure in premature cardiovascular disease patients homozygous for the MTHFR 677C > T polymorphism. Genomics. 2020;112:669–676. doi: 10.1016/j.ygeno.2019.04.019. PubMed DOI

Tian X., Yu C., Shi L., Li D., Chen X., Xia D., Zhou J., Xu W., Ma C., Gu L., et al. MicroRNA-199a-5p aggravates primary hypertension by damaging vascular endothelial cells through inhibition of autophagy and promotion of apoptosis. Exp. Ther. Med. 2018;16:595–602. doi: 10.3892/etm.2018.6252. PubMed DOI PMC

Zhou Y., Pang B., Xiao Y., Zhou S., He B., Zhang F., Liu W., Peng H., Li P. The protective microRNA-199a-5p-mediated unfolded protein response in hypoxic cardiomyocytes is regulated by STAT3 pathway. J. Physiol. Biochem. 2019;75:73–81. doi: 10.1007/s13105-018-0657-6. PubMed DOI

Liu Y., Liu G., Zhang H., Wang J. MiRNA-199a-5p influences pulmonary artery hypertension via downregulating Smad3. Biochem. Biophys. Res. Commun. 2016;473:859–866. doi: 10.1016/j.bbrc.2016.03.140. PubMed DOI

Wang J., Yu G. A Systems Biology Approach to Characterize Biomarkers for Blood Stasis Syndrome of Unstable Angina Patients by Integrating MicroRNA and Messenger RNA Expression Profiling. Evid.-Based Complement. Altern. Med. 2013;2013:510208. doi: 10.1155/2013/510208. PubMed DOI PMC

Yu L., Gu T., Shi E., Wang Y., Fang Q., Wang C. Dysregulation of renal microRNA expression after deep hypothermic circulatory arrest in rats. Eur. J. Cardiothorac Surg. 2016;49:1725–1731. doi: 10.1093/ejcts/ezv460. PubMed DOI

Hirt M.N., Werner T., Indenbirken D., Alawi M., Demin P., Kunze A.C., Stenzig J., Starbatty J., Hansen A., Fiedler J., et al. Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology. J. Mol. Cell. Cardiol. 2015;81:1–9. doi: 10.1016/j.yjmcc.2015.01.008. PubMed DOI

Aguado-Fraile E., Ramos E., Conde E., Rodríguez M., Martín-Gómez L., Lietor A., Candela Á., Ponte B., Liaño F., García-Bermejo M.L. A Pilot Study Identifying a Set of microRNAs As Precise Diagnostic Biomarkers of Acute Kidney Injury. PLoS ONE. 2015;10:e0127175. doi: 10.1371/journal.pone.0127175. PubMed DOI PMC

Ma H., Chen P., Sang C., Huang D., Geng Q., Wang L. Modulation of apoptosis-related microRNAs following myocardial infarction in fat-1 transgenic mice vs wild-type mice. J. Cell. Mol. Med. 2018;22:5698–5707. doi: 10.1111/jcmm.13846. PubMed DOI PMC

Qiao X.R., Wang L., Liu M., Tian Y., Chen T. MiR-210-3p attenuates lipid accumulation and inflammation in atherosclerosis by repressing IGF2. Biosci. Biotechnol. Biochem. 2020;84:321–329. doi: 10.1080/09168451.2019.1685370. PubMed DOI

Derda A.A., Pfanne A., Bwangär C., Schimmel K., Kennel P.J., Xiao K., Schulze P.C., Bauersachs J., Thum T. Blood-based microRNA profiling in patients with cardiac amyloidosis. PLoS ONE. 2018;13:e0204235. PubMed PMC

Verjans R., Peters T., Beaumont F.J., van Leeuwen R., van Herwaarden T., Verhesen W., Munts C., Bijnen M., Henkens M., Diez J., et al. MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure. Hypertension. 2018;71:280–288. doi: 10.1161/HYPERTENSIONAHA.117.10094. PubMed DOI

Zhuang X., Li R., Maimaitijiang A., Liu R., Yan F., Hu H., Gao X., Shi H. miR-221-3p inhibits oxidized low-density lipoprotein induced oxidative stress and apoptosis via targeting a disintegrin and metalloprotease-22. J. Cell. Biochem. 2019;120:6304–6314. doi: 10.1002/jcb.27917. PubMed DOI

Pereira-da-Silva T., Coutinho Cruz M., Carrusca C., Cruz Ferreira R., Napoleão P., Mota Carmo M. Circulating microRNA profiles in different arterial territories of stable atherosclerotic disease: A systematic review. Am. J. Cardiovasc. Dis. 2018;8:1–13. PubMed PMC

Coffey S., Williams M.J., Phillips L.V., Galvin I.F., Bunton R.W., Jones G.T. Integrated microRNA and messenger RNA analysis in aortic stenosis. Sci. Rep. 2016;6:36904. doi: 10.1038/srep36904. PubMed DOI PMC

Coskunpinar E., Cakmak H.A., Kalkan A.K., Tiryakioglu N.O., Erturk M., Ongen Z. Circulating miR-221-3p as a novel marker for early prediction of acute myocardial infarction. Gene. 2016;591:90–96. doi: 10.1016/j.gene.2016.06.059. PubMed DOI

Sørensen S.S., Nygaard A.B., Nielsen M.Y., Jensen K., Christensen T. miRNA expression profiles in cerebrospinal fluid and blood of patients with acute ischemic stroke. Transl. Stroke Res. 2014;5:711–718. doi: 10.1007/s12975-014-0364-8. PubMed DOI

Gusar V.A., Timofeeva A.V., Zhanin I.S., Shram S.I., Pinelis V.G. Estimation of Time-Dependent microRNA Expression Patterns in Brain Tissue, Leukocytes, and Blood Plasma of Rats under Photochemically Induced Focal Cerebral Ischemia. Mol. Biol. 2017;51:683–695. doi: 10.1134/S0026893317040100. PubMed DOI

Nie X., Chen Y., Tan J., Dai Y., Mao W., Qin G., Ye S., Sun J., Yang Z., Chen J. MicroRNA-221-3p promotes pulmonary artery smooth muscle cells proliferation by targeting AXIN2 during pulmonary arterial hypertension. Vascul. Pharmacol. 2019;116:24–35. doi: 10.1016/j.vph.2017.07.002. PubMed DOI

Villard A., Marchand L., Thivolet C., Rome S. Diagnostic Value of Cell-free Circulating MicroRNAs for Obesity and Type 2 Diabetes: A Meta-analysis. J. Mol. Biomark. Diagn. 2015;6:251. doi: 10.4172/2155-9929.1000251. PubMed DOI PMC

Wang L., Xu L., Xu M., Liu G., Xing J., Sun C., Ding H. Obesity-Associated MiR-342-3p Promotes Adipogenesis of Mesenchymal Stem Cells by Suppressing CtBP2 and Releasing C/EBPα from CtBP2 Binding. Cell. Physiol. Biochem. 2015;35:2285–2298. doi: 10.1159/000374032. PubMed DOI

Hezova R., Slaby O., Faltejskova P., Mikulkova Z., Buresova I., Raja K.R., Hodek J., Ovesna J., Michalek J. microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell. Immunol. 2010;260:70–74. doi: 10.1016/j.cellimm.2009.10.012. PubMed DOI

Eissa S., Matboli M., Bekhet M.M. Clinical verification of a novel urinary microRNA panal: 133b, -342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis. Biomed. Pharmacother. 2016;83:92–99. doi: 10.1016/j.biopha.2016.06.018. PubMed DOI

Cheng S., Cui Y., Fan L., Mu X., Hua Y. T2DM inhibition of endothelial miR-342-3p facilitates angiogenic dysfunction via repression of FGF11 signaling. Biochem. Biophys. Res. Commun. 2018;503:71–78. doi: 10.1016/j.bbrc.2018.05.179. PubMed DOI

Khalyfa A., Kheirandish-Gozal L., Bhattacharjee R., Khalyfa A.A., Gozal D. Circulating microRNAs as Potential Biomarkers of Endothelial Dysfunction in Obese Children. Chest. 2016;149:786–800. doi: 10.1378/chest.15-0799. PubMed DOI PMC

Hoekstra M. MicroRNA-499-5p: A therapeutic target in the context of cardiovascular disease. Ann. Transl. Med. 2016;4:539. doi: 10.21037/atm.2016.11.61. PubMed DOI PMC

Zhao L., Wang B., Zhang W., Sun L. Effect of miR-499a-5p on damage of cardiomyocyte induced by hypoxia-reoxygenation via downregulating CD38 protein. J. Cell. Biochem. 2020;121:996–1004. doi: 10.1002/jcb.29334. PubMed DOI

Neshati V., Mollazadeh S., Fazly Bazzaz B.S., de Vries A.A.F., Mojarrad M., Naderi-Meshkin H., Neshati Z., Mirahmadi M., Kerachian M.A. MicroRNA-499a-5p Promotes Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells to Cardiomyocytes. Appl. Biochem. Biotechnol. 2018;186:245–255. doi: 10.1007/s12010-018-2734-2. PubMed DOI

Boštjančič E., Zidar N., Glavač D. MicroRNAs and cardiac sarcoplasmic reticulum calcium ATPase-2 in human myocardial infarction: Expression and bioinformatic analysis. BMC Genom. 2012;13:552. doi: 10.1186/1471-2164-13-552. PubMed DOI PMC

Salinas J., Lin H., Aparico H.J., Huan T., Liu C., Rong J., Beiser A., Himali J.J., Freedman J.E., Larson M.G., et al. Whole blood microRNA expression associated with stroke: Results from the Framingham Heart Study. PLoS ONE. 2019;14:e0219261. doi: 10.1371/journal.pone.0219261. PubMed DOI PMC

Baldeón Rojas L., Weigelt K., de Wit H., Ozcan B., van Oudenaren A., Sempértegui F., Sijbrands E., Grosse L., van Zonneveld A.J., Drexhage H.A., et al. Study on inflammation-related genes and microRNAs, with special emphasis on the vascular repair factor HGF and miR-574-3p, in monocytes and serum of patients with T2D. Diabetol. Metab. Syndr. 2016;8:6. doi: 10.1186/s13098-015-0113-5. PubMed DOI PMC

Hromadnikova I., Kotlabova K., Dvorakova L., Krofta L., Sirc J. Substantially Altered Expression Profile of Diabetes/Cardiovascular/Cerebrovascular Disease Associated microRNAs in Children Descending from Pregnancy Complicated by Gestational Diabetes Mellitus-One of Several Possible Reasons for an Increased Cardiovascular Risk. Cells. 2020;9:1557. PubMed PMC

Yoffe L., Polsky A., Gilam A., Raff C., Mecacci F., Ognibene A., Crispi F., Gratacós E., Kanety H., Mazaki-Tovi S., et al. Early diagnosis of gestational diabetes mellitus using circulating microRNAs. Eur. J. Endocrinol. 2019;181:565–577. doi: 10.1530/EJE-19-0206. PubMed DOI

Légaré C., Desgagné V., Poirier C., Thibeault K., White F., Clément A.A., Scott M.S., Jacques P.É., Perron P., Guérin R., et al. First trimester plasma microRNAs levels predict Matsuda Index-estimated insulin sensitivity between 24th and 29th week of pregnancy. BMJ Open Diabetes Res. Care. 2022;10:e002703. doi: 10.1136/bmjdrc-2021-002703. PubMed DOI PMC

Juchnicka I., Kuźmicki M., Niemira M., Bielska A., Sidorkiewicz I., Zbucka-Krętowska M., Krętowski A.J., Szamatowicz J. miRNAs as Predictive Factors in Early Diagnosis of Gestational Diabetes Mellitus. Front. Endocrinol. 2022;13:839344. doi: 10.3389/fendo.2022.839344. PubMed DOI PMC

Zhang L., Zhang T., Sun D., Cheng G., Ren H., Hong H., Chen L., Jiao X., Du Y., Zou Y., et al. Diagnostic value of dysregulated microribonucleic acids in the placenta and circulating exosomes in gestational diabetes mellitus. J. Diabetes Investig. 2021;12:1490–1500. doi: 10.1111/jdi.13493. PubMed DOI PMC

Wang J., Pan Y., Dai F., Wang F., Qiu H., Huang X. Serum miR-195-5p is upregulated in gestational diabetes mellitus. J. Clin. Lab. Anal. 2020;34:e23325. doi: 10.1002/jcla.23325. PubMed DOI PMC

Sørensen A.E., van Poppel M.N.M., Desoye G., Damm P., Simmons D., Jensen D.M., Dalgaard L.T., The DALI Core Investigator Group The Predictive Value of miR-16, -29a and -134 for Early Identification of Gestational Diabetes: A Nested Analysis of the DALI Cohort. Cells. 2021;10:170. doi: 10.3390/cells10010170. PubMed DOI PMC

Zhao C., Dong J., Jiang T., Shi Z., Yu B., Zhu Y., Chen D., Xu J., Huo R., Dai J., et al. Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS ONE. 2011;6:e23925. doi: 10.1371/journal.pone.0023925. PubMed DOI PMC

Kennedy M., Cartland S., Saravanan P., Simpson N., Scott E., Forbes K. miR-1-3p and miR-133-3p are altered in maternal serum EVs and placenta in pregnancies complicated by gestational diabetes with large-for-gestational age babies. Endocr. Abstr. 2019;65:349. doi: 10.1530/endoabs.65.P349. DOI

Wang F., Zhang X., Zhou H. Role of cell free microRNA-19a and microRNA-19b in gestational diabetes mellitus patients. 3 Biotech. 2019;9:406. doi: 10.1007/s13205-019-1952-9. PubMed DOI PMC

Feng Y., Qu X., Chen Y., Feng Q., Zhang Y., Hu J., Li X. MicroRNA-33a-5p sponges to inhibit pancreatic β-cell function in gestational diabetes mellitus LncRNA DANCR. Reprod. Biol. Endocrinol. 2020;18:61. doi: 10.1186/s12958-020-00618-8. PubMed DOI PMC

Sebastiani G., Guarino E., Grieco G.E., Formichi C., Delli Poggi C., Ceccarelli E., Dotta F. Circulating microRNA (miRNA) Expression Profiling in Plasma of Patients with Gestational Diabetes Mellitus Reveals Upregulation of miRNA miR-330-3p. Front. Endocrinol. 2017;8:345. doi: 10.3389/fendo.2017.00345. PubMed DOI PMC

Stirm L., Huypens P., Sass S., Batra R., Fritsche L., Brucker S., Abele H., Hennige A.M., Theis F., Beckers J., et al. Maternal whole blood cell miRNA-340 is elevated in gestational diabetes and inversely regulated by glucose and insulin. Sci. Rep. 2018;8:1366. doi: 10.1038/s41598-018-19200-9. PubMed DOI PMC

Xu K., Bian D., Hao L., Huang F., Xu M., Qin J., Liu Y. microRNA-503 contribute to pancreatic beta cell dysfunction by targeting the mTOR pathway in gestational diabetes mellitus. EXCLI J. 2017;16:1177–1187. PubMed PMC

Liu L., Zhang J., Liu Y. MicroRNA-1323 serves as a biomarker in gestational diabetes mellitus and aggravates high glucose-induced inhibition of trophoblast cell viability by suppressing TP53INP1. Exp. Ther. Med. 2021;21:230. PubMed PMC

Hromadnikova I., Kotlabova K., Krofta L. Cardiovascular Disease-Associated MicroRNA Dysregulation during the First Trimester of Gestation in Women with Chronic Hypertension and Normotensive Women Subsequently Developing Gestational Hypertension or Preeclampsia with or without Fetal Growth Restriction. Biomedicines. 2022;10:256. PubMed PMC

Hromadnikova I., Kotlabova K., Krofta L. First-Trimester Screening for Fetal Growth Restriction and Small-for-Gestational-Age Pregnancies without Preeclampsia Using Cardiovascular Disease-Associated MicroRNA Biomarkers. Biomedicines. 2022;10:718. doi: 10.3390/biomedicines10030718. PubMed DOI PMC

Hromadnikova I., Kotlabova K., Krofta L. First Trimester Prediction of Preterm Delivery in the Absence of Other Pregnancy-Related Complications Using Cardiovascular-Disease Associated MicroRNA Biomarkers. Int. J. Mol. Sci. 2022;23:3951. doi: 10.3390/ijms23073951. PubMed DOI PMC

Hromadnikova I., Kotlabova K., Dvorakova L., Krofta L. Diabetes Mellitus and Cardiovascular Risk Assessment in Mothers with a History of Gestational Diabetes Mellitus Based on Postpartal Expression Profile of MicroRNAs Associated with Diabetes Mellitus and Cardiovascular and Cerebrovascular Diseases. Int. J. Mol. Sci. 2020;21:2437. doi: 10.3390/ijms21072437. PubMed DOI PMC

Shah B.R., Retnakaran R., Booth G.L. Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care. 2008;31:1668–1669. doi: 10.2337/dc08-0706. PubMed DOI PMC

Kramer C.K., Campbell S., Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: A systematic review and meta-analysis. Diabetologia. 2019;62:905–914. doi: 10.1007/s00125-019-4840-2. PubMed DOI

Yu Y., Soohoo M., Sørensen H.T., Li J., Arah O.A. Gestational Diabetes Mellitus and the Risks of Overall and Type-Specific Cardiovascular Diseases: A Population- and Sibling-Matched Cohort Study. Diabetes Care. 2022;45:151–159. doi: 10.2337/dc21-1018. PubMed DOI PMC

Bentley-Lewis R. Late cardiovascular consequences of gestational diabetes mellitus. Semin. Reprod. Med. 2009;27:322–329. doi: 10.1055/s-0029-1225260. PubMed DOI PMC

Shostrom D.C.V., Sun Y., Oleson J.J., Snetselaar L.G., Bao W. History of Gestational Diabetes Mellitus in Relation to Cardiovascular Disease and Cardiovascular Risk Factors in US Women. Front. Endocrinol. 2017;8:144. doi: 10.3389/fendo.2017.00144. PubMed DOI PMC

Peng Y.S., Lin J.R., Cheng B.H., Ho C., Lin Y.H., Shen C.H., Tsai M.H. Incidence and relative risk for developing cancers in women with gestational diabetes mellitus: A nationwide cohort study in Taiwan. BMJ Open. 2019;9:e024583. doi: 10.1136/bmjopen-2018-024583. PubMed DOI PMC

Han K.T., Cho G.J., Kim E.H. Evaluation of the Association between Gestational Diabetes Mellitus at First Pregnancy and Cancer within 10 Years Postpartum Using National Health Insurance Data in South Korea. Int. J. Environ. Res. Public Health. 2018;15:2646. doi: 10.3390/ijerph15122646. PubMed DOI PMC

Liu Y., Chen X., Sheng J., Sun X., Chen G.Q., Zhao M., Chen Q. Complications of Pregnancy and the Risk of Developing Endometrial or Ovarian Cancer: A Case-Control Study. Front. Endocrinol. 2021;12:642928. doi: 10.3389/fendo.2021.642928. PubMed DOI PMC

Simon J., Goueslard K., Arveux P., Bechraoui-Quantin S., Petit J.M., Quantin C. Increased Risk of Hospitalization for Pancreatic Cancer in the First 8 Years after a Gestational Diabetes Mellitus regardless of Subsequent Type 2 Diabetes: A Nationwide Population-Based Study. Cancers. 2021;13:308. doi: 10.3390/cancers13020308. PubMed DOI PMC

Fuchs O., Sheiner E., Meirovitz M., Davidson E., Sergienko R., Kessous R. The association between a history of gestational diabetes mellitus and future risk for female malignancies. Arch. Gynecol. Obstet. 2017;295:731–736. PubMed

Dawson S.I. Long-term risk of malignant neoplasm associated with gestational glucose intolerance. Cancer. 2004;100:149–155. doi: 10.1002/cncr.20013. PubMed DOI

Perrin M.C., Terry M.B., Kleinhaus K., Deutsch L., Yanetz R., Tiram E., Calderon-Margalit R., Friedlander Y., Paltiel O., Harlap S. Gestational diabetes and the risk of breast cancer among women in the Jerusalem Perinatal Study. Breast Cancer Res. Treat. 2008;108:129–135. PubMed

Perrin M.C., Terry M.B., Kleinhaus K., Deutsch L., Yanetz R., Tiram E., Calderon R., Friedlander Y., Paltiel O., Harlap S. Gestational diabetes as a risk factor for pancreatic cancer: A prospective cohort study. BMC Med. 2007;5:25. doi: 10.1186/1741-7015-5-25. PubMed DOI PMC

Metzger B.E., Coustan D.R. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee. Diabetes Care. 1998;21:B161–B167. PubMed

Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408. PubMed

Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of re-al-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:research0034.1. PubMed PMC

Hromadnikova I., Kotlabova K., Hympanova L., Krofta L. Gestational hypertension, preeclampsia and intrauterine growth restriction induce dysregulation of cardiovascular and cerebrovascular disease associated microRNAs in maternal whole peripheral blood. Thromb. Res. 2016;137:126–140. PubMed

Andersen C.L., Jensen J.L., Ørntoft T.F. Normalization of real-time quantitative reverse transcription-PCR data: A model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon can-cer data sets. Cancer Res. 2004;64:5245–5250. PubMed

Benjamini Y., Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B. 1995;57:289–300.

Abnormal microRNA expression profile at early stages of gestation in pregnancies destined to develop placenta previa

First-trimester predictive models for adverse pregnancy outcomes-a base for implementation of strategies to prevent cardiovascular disease development

First-Trimester Screening for Miscarriage or Stillbirth-Prediction Model Based on MicroRNA Biomarkers

Pathogenesis of Pregnancy-Related Complications

First-Trimester Screening for HELLP Syndrome-Prediction Model Based on MicroRNA Biomarkers and Maternal Clinical Characteristics

Novel First-Trimester Prediction Model for Any Type of Preterm Birth Occurring before 37 Gestational Weeks in the Absence of Other Pregnancy-Related Complications Based on Cardiovascular Disease-Associated MicroRNAs and Basic Maternal Clinical Characteristics